UNSPSC 51111635: Eniluracil

This classification denotes a pyrimidine antagonist and dihydropyrimidine dehydrogenase inhibitor with the molecular formula C6H4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2E2W0W5XIU, chemically known as 2,4(1h,3h)-pyrimidinedione, 5-ethynyl- but generally known as eniluracil, which bears US NIH Compound Identifier 43157. European Medicines Agency schedules Eniluracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13674MIG.

UNSPSC 51111635 Eniluracil is a Commodity code covering the procurement of eniluracil, a pharmaceutical compound used in oncology treatment regimens. State and local governments procure this drug primarily through public health departments, state Medicaid agencies, correctional health systems, and county hospitals for administration to eligible patient populations. The pharmaceutical is typically sourced through state group purchasing organizations, competitive bidding processes, or existing state drug contracts that bundle oncology medications. Eniluracil appears in procurement activity as part of broader cancer treatment protocols, often bundled with complementary chemotherapy agents or acquired as a line item within standing pharmaceutical supply agreements.

The recent-opportunities block contains no records for this code, indicating minimal or no documented state and local procurement activity under UNSPSC 51111635 in the recent period. Without posted solicitations, RFPs, RFQs, or ITBs to reference, geographic distribution and issuing-body patterns cannot be determined from current market signals. Firms evaluating this code should verify current demand directly with state pharmacy benefit managers, Medicaid procurement offices, and correctional health administrators, as oncology pharmaceutical procurement often flows through standing contracts or master agreements that may not generate individual public notices.